{
    "id": "34798e95-3e5e-779b-e063-6394a90a319e",
    "indications": {
        "text": "asceniv ( immune globulin intravenous , human \u2013 slra ) 10 % immune globulin liquid intravenous injection , indicated treatment primary humoral immunodeficiency ( pi ) adults adolescents ( 12 17 years age ) . pi includes , limited , humoral immune defect congenital agammaglobulinemia , common variable immunodeficiency ( cvid ) , x-linked agammaglobulinemia , wiskott-aldrich syndrome , severe combined immunodeficiencies ( scid ) .",
        "doid_entities": [
            {
                "text": "agammaglobulinemia (DOID:2583)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2583"
            },
            {
                "text": "common variable immunodeficiency (DOID:12177)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_12177"
            },
            {
                "text": "x-linked agammaglobulinemia (DOID:14179)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_14179"
            },
            {
                "text": "wiskott-aldrich syndrome (DOID:9169)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9169"
            },
            {
                "text": "syndrome (DOID:225)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_225"
            },
            {
                "text": "scid (DOID:627)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_627"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "immunodeficiency",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_101997"
            },
            {
                "disease": "wiskott-aldrich syndrome",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_906"
            },
            {
                "disease": "severe combined immunodeficiencies",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_183660"
            }
        ]
    },
    "contraindications": {
        "text": "intravenous . dose initial infusion rate maintenance infusion rate ( tolerated ) 300-800 mg/kg every 3- 4 weeks 0.5 mg/kg/min ( 0.005 ml/kg/min ) first 15 minutes increase gradually every 15 minutes ( tolerated ) 8 mg/kg/min ( 0.08 ml/kg/min ) ensure patients pre-existing renal insufficiency volume depleted ; discontinue asceniv renal function deteriorates . [ 5.3 ] patients risk renal dysfunction thrombotic events , administer asceniv minimum infusion rate practicable . [ 5.2 , 5.3 ]",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "asceniv supplied single-use , tamper-evident vial . components used packaging asceniv made natural rubber latex . asceniv supplied 50 ml size containing 5 grams protein ( ndc 69800-0250-1 ) . store 2 8\u00b0c ( 36 46\u00b0f ) 36 months date manufacture . freeze . product may stored 4 weeks \u2264 25\u00b0 c ( 77\u00b0 f ) . storage room temperature product must used discarded .",
    "adverseReactions": "asceniv contraindicated : patients anaphylactic severe systemic reaction human immune globulin . iga-deficiency patients antibodies iga history hypersensitivity .",
    "ingredients": [
        {
            "name": "GLYCINE",
            "code": "TE7660XO1C",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15428"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_26710"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53426"
        },
        {
            "name": "WATER O-18",
            "code": "7QV8F8BYNJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "HUMAN IMMUNOGLOBULIN G",
            "code": "66Y330CJHS",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00028"
        }
    ],
    "organization": "ADMA Biologics, Inc.",
    "name": "ASCENIV",
    "effectiveTime": "20250506",
    "indications_original": "ASCENIV (immune globulin intravenous, human \u2013 slra) is a 10% immune globulin liquid for intravenous injection, indicated for the\n\t\t\t\t\t\t\ttreatment of primary humoral immunodeficiency (PI) in adults and adolescents (12 to 17 years of age). PI includes, but is not limited to,\n\t\t\t\t\t\t\tthe humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency (CVID), X-linked agammaglobulinemia,\n\t\t\t\t\t\t\tWiskott-Aldrich syndrome, and severe combined immunodeficiencies (SCID).",
    "contraindications_original": "For intravenous use only. Dose Initial Infusion Rate Maintenance Infusion Rate (if tolerated) 300-800 mg/kg every 3- 4 weeks 0.5 mg/kg/min (0.005 mL/kg/min) for the first 15 minutes Increase gradually every 15 minutes (if tolerated) up to 8 mg/kg/min (0.08 mL/kg/min) Ensure that patients with pre-existing renal insufficiency are not volume depleted; discontinue ASCENIV if renal function \n\t\t\t\t\t\t\t\t\t\tdeteriorates. [5.3] For patients at risk of renal dysfunction or thrombotic events, administer ASCENIV at the minimum infusion rate practicable. [5.2, 5.3]",
    "warningsAndPrecautions_original": "ASCENIV is supplied in a single-use, tamper-evident vial. The components used in the packaging for ASCENIV are not made with natural rubber latex. ASCENIV is supplied in 50 mL size containing 5 grams of protein (NDC 69800-0250-1).\n                  \n                  \n                     Store at 2 to 8\u00b0C (36 to 46\u00b0F) for up to 36 months from the date of manufacture. Do not freeze.\n                     Product may be stored up to 4 weeks at \u2264 25\u00b0 C (77\u00b0 F). After storage at room temperature product must be used or discarded.",
    "adverseReactions_original": "ASCENIV is contraindicated in:\n                  \n                     patients who have had an anaphylactic or severe systemic reaction to the administration of human immune globulin.\n                     IgA-deficiency patients with antibodies to IgA and a history of hypersensitivity.",
    "drug": [
        {
            "name": "ASCENIV",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15428"
        }
    ]
}